Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab vs High Dose Interferon or Ipilimumab in High Risk Resected Melanoma
NCT02506153Phase 3Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Nov 2015
- Primary completion
- Sep 2023
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 3
01
Overview
Phase 3, randomised, open-label trial of pembrolizumab in melanoma (2 arms), sponsored by National Cancer Institute. Primary endpoint: Overall Survival at 5 years. Started Nov 2015; status: active, not recruiting.
02
Drugs
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT02506153.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02506153.